TNFRSF8 and lymphoma: CD30 is an ideal therapeutic target as it is expressed in many lymphomas while having very low expression on normal tissue.1,2 In healthy tissue, the majority of CD30 expression is limited to activated B cells, T cells, and natural killer cells, although activated lymphocytes make up less than 1% of the circulating cells in the blood.